Impact of polymer hydrophilicity on biocompatibility: Implication for DES polymer design
- 19 May 2008
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 90A (1), 133-141
- https://doi.org/10.1002/jbm.a.32057
Abstract
Polymer coatings are essential for local delivery of drug from the stent platform. In designing a DES, it is critical to balance the hydrophilic and hydrophobic components of the polymer system to obtain optimal biocompatibility, while maintaining controlled drug elution. This study investigates the impact of polymer composition of the BioLinx™ polymer blend on in vitro biocompatibility, as measured by monocytic adhesion. Comparable evaluation was performed with polymers similar to those utilized in various DES that are currently being marketed. Relative hydrophilicities of polymer surfaces were determined through contact angle measurements and surface analyses. Polymer biocompatibility was evaluated in a novel in vitro assay system in which activated monocyte cells were exposed to polymer coated on 96‐well plates. Enhanced monocyte adhesion was observed with polymers of a more hydrophobic nature, whereas those which were more hydrophilic did not induce activated monocyte adhesion. Our data supports the hypothesis that polymer composition is a feature that dictates in vitro biocompatibility as measured by monocyte driven inflammation. Monocyte adhesion has been shown to induce local inflammation as well as promote vascular cell proliferation factors contributing to in stent restenosis (Rogers et al., Arterioscler Thromb Vasc Biol 1996;16:1312–1318). Observed results suggest hydrophobic but not hydrophilic polymer surfaces support adhesion of activated monoctyes to the polymer scaffold. The proprietary DES polymer blend BioLinx has a hydrophilic surface architecture and does not induce an inflammatory response as measured by these in vitro assays. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009Keywords
This publication has 23 references indexed in Scilit:
- Development of a novel biocompatible polymer system for extended drug release in a next‐generation drug‐eluting stentJournal of Biomedical Materials Research Part A, 2007
- Vascular Responses to Drug Eluting StentsArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Vascular Pathology of Drug-Eluting StentsHerz Kardiovaskuläre Erkrankungen, 2007
- Late stent thrombosis in drug-eluting stents: return of the 'VB syndrome'Nature Clinical Practice Cardiovascular Medicine, 2006
- Polymers, Drug Release, and Drug‐Eluting StentsJournal of Interventional Cardiology, 2006
- Pushing Drug-Eluting Stents Into Uncharted TerritoryCirculation, 2006
- Polyglycolic Acid-Induced Inflammation: Role of Hydrolysis and Resulting Complement ActivationTissue Engineering, 2006
- Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary LesionsCirculation, 2004
- A chicken in every pot and a drug-eluting stent in every lesion.Circulation, 2004
- Monocyte Recruitment and Neointimal Hyperplasia in RabbitsArteriosclerosis, Thrombosis, and Vascular Biology, 1996